Cargando…

Use of Renin-Angiotensin System Inhibitors Is Associated with Reduction of Fracture Risk in Hemodialysis Patients

BACKGROUND: Patients with chronic kidney disease, especially those undergoing dialysis treatment and having secondary hyperparathyroidism, have a high risk of bone fracture. The renin-angiotensin system (RAS) is associated with osteoclastic bone resorption. We aimed to examine whether the use of RAS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamamoto, Suguru, Kido, Ryo, Onishi, Yoshihiro, Fukuma, Shingo, Akizawa, Tadao, Fukagawa, Masafumi, Kazama, Junichiro J., Narita, Ichiei, Fukuhara, Shunichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4395204/ https://www.ncbi.nlm.nih.gov/pubmed/25874620 http://dx.doi.org/10.1371/journal.pone.0122691

Ejemplares similares

Type I Angiotensin II Receptor Blockade Reduces Uremia‐Induced Deterioration of Bone Material Properties
por: Wakamatsu, Takuya, et al.
Publicado: (2020)

Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy
por: Yokoyama, Keitaro, et al.
Publicado: (2017)

Contribution of dysregulated serum magnesium to mortality in hemodialysis patients with secondary hyperparathyroidism: a 3-year cohort study
por: Kurita, Noriaki, et al.
Publicado: (2015)

Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism
por: Kato, Chihiro, et al.
Publicado: (2020)

Impact of cinacalcet introduction on MBD management: the MBD-5D study in Japan
por: Fukuma, Shingo, et al.
Publicado: (2013)

Population-level associations of achievement of targets for bone-mineral markers with survival in haemodialysis patients with mildly elevated intact-PTH levels: a case-cohort study
por: Fukuma, Shingo, et al.
Publicado: (2019)

PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2016)

The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study
por: Ogata, Hiroaki, et al.
Publicado: (2017)

Association of coping strategies with mortality and health-related quality of life in hemodialysis patients: The Japan Dialysis Outcomes and Practice Patterns Study
por: Niihata, Kakuya, et al.
Publicado: (2017)

Effectiveness of cinacalcet treatment for secondary hyperparathyroidism on hospitalization: Results from the MBD-5D study
por: Asada, Shinji, et al.
Publicado: (2019)

Length of hospital stay is associated with a decline in activities of daily living in hemodialysis patients: a prospective cohort study
por: Kamitani, Tsukasa, et al.
Publicado: (2020)

Dialysis‐related practice patterns among hemodialysis patients with cancer
por: Nishiwaki, Hiroki, et al.
Publicado: (2018)

Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level: an analysis from the MBD-5D study
por: Asada, Shinji, et al.
Publicado: (2020)

Development and validation of a prediction model for loss of physical function in elderly hemodialysis patients
por: Fukuma, Shingo, et al.
Publicado: (2018)

Both low and high serum ferritin levels predict mortality risk in hemodialysis patients without inflammation
por: Shoji, Tetsuo, et al.
Publicado: (2016)

Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study
por: Tanaka, Motoko, et al.
Publicado: (2016)

First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties
por: Kazama, Junichiro James, et al.
Publicado: (2022)

Impact of nutritional index on the association between phosphorus concentrations and mortality in haemodialysis patients: a cohort study from dialysis outcomes and practice pattern study in Japan
por: Fukuma, Shingo, et al.
Publicado: (2017)

Development of a new risk model for predicting cardiovascular events among hemodialysis patients: Population-based hemodialysis patients from the Japan Dialysis Outcome and Practice Patterns Study (J-DOPPS)
por: Matsubara, Yukiko, et al.
Publicado: (2017)

Haemoglobin concentration and survival of haemodialysis patients before and after experiencing cardiovascular disease: a cohort study from Japanese dialysis outcomes and practice pattern study (J-DOPPS)
por: Kido, Ryo, et al.
Publicado: (2019)

Intact parathyroid hormone and whole parathyroid hormone assay results disagree in hemodialysis patients under cinacalcet hydrochloride therapy
por: Koda, Ryo, et al.
Publicado: (2014)

Dialysis physicians’ referral behaviors for hemodialysis patients suspected of having cancer: A vignette-based questionnaire study
por: Fukuma, Shingo, et al.
Publicado: (2018)

Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients
por: Shigematsu, Takashi, et al.
Publicado: (2018)

Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2017)

Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis
por: Yokoyama, Keitaro, et al.
Publicado: (2019)

Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan
por: Shigematsu, Takashi, et al.
Publicado: (2018)

Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients
por: Akizawa, Tadao, et al.
Publicado: (2021)

Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study
por: Akizawa, Tadao, et al.
Publicado: (2018)

Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis
por: Shigematsu, Takashi, et al.
Publicado: (2020)

Control of severe hyperparathyroidism in dialysis patients with nodular hyperplasia
por: Fukagawa, Masafumi, et al.
Publicado: (2008)

Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial
por: Inaba, Masaaki, et al.
Publicado: (2021)

Dietary Patterns and Clinical Outcomes in Hemodialysis Patients in Japan: A Cohort Study
por: Tsuruya, Kazuhiko, et al.
Publicado: (2015)

Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism
por: Tokumoto, Masanori, et al.
Publicado: (2022)

In Reply to “Letter Regarding ‘Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial’”
por: Inaba, Masaaki, et al.
Publicado: (2022)

Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia
por: Koiwa, Fumihiko, et al.
Publicado: (2023)

Dialysis disequilibrium syndrome induced by neoplastic meningitis in a patient receiving maintenance hemodialysis
por: Tsuchida, Yohei, et al.
Publicado: (2013)

A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism
por: Yokoyama, Keitaro, et al.
Publicado: (2017)

Variations and characteristics of quality indicators for maintenance hemodialysis patients: A systematic review
por: Niihata, Kakuya, et al.
Publicado: (2018)

Some Aspects of the Renin-Angiotensin- System in Hemodialysis Patients
por: Malik, Umar, et al.
Publicado: (2015)

Interdialytic Weight Gain Effects on Hemoglobin Concentration and Cardiovascular Events
por: Hara, Takashi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nr3crad8d4hbh8dc757s9uv69i